CLAIMS

1. Use of an aqueous solution comprising:
    a) adrenalin; and
    b) an antidepressant, wherein the antidepressant is chosen from the group consisting of amitriptyline, amoxapine, amitriptylinoxide, butriptyline, clomipramine, demexiptiline, dibenzepin, dimetacrine, dosulepin, doxepin, imipraminoxide, lofepramine, maprotiline, mianserin, melitracen, metapramine, nitroxazepine, nortriptyline, noxiptiline, pipofezine, propizepine, protriptyline, quinupramine, amineptine and trimipramine, or one of its pharmaceutically acceptable salts,

    and wherein said aqueous solution is to be administered at a dose of adrenalin comprised between 0.05 mg and 0.35 mg and at a dose of said antidepressant comprised between 0.1 mg and 3 mg,
    in the manufacture of a medicament for the treatment of shocks.

2. The use according to claim 1, wherein the antidepressant is trimipramine or one of its pharmaceutically acceptable salts.

3. The use according to claim 1, wherein the antidepressant is doxepin or one of its pharmaceutically acceptable salts.

4. The use according to any one of claims 1 to 3, wherein adrenalin is at a concentration comprised between 0.05 mg/ml and 1.0 mg/ml in said solution.

5. The use according to any one of claims 1 to 4, wherein the antidepressant is at a concentration comprised between 0.1 mg/ml and 10 mg/ml in said solution.

6. The use according to any one of claims 1 to 5, wherein said aqueous solution consists of adrenalin, an antidepressant, sodium chloride, a preservative agent and water.

7. Use of an aqueous solution comprising adrenalin and an antidepressant in the manufacture of a medicament for the treatment of shocks, wherein said aqueous solution is to be administered at a dose of adrenalin comprised between 0.05 mg and 0.35 mg and at a dose of said antidepressant comprised between 0.1 mg and 3 mg.

8. The use according to claim 1 or claim 7 wherein the type of shock is selected from the group consisting of: anaphylactic shock, cardiac arrest, and cardiovascular distress associated with anaphylactic shock, hemorragic shock, traumatic shock, infectious shock and secondary shock due to cardiac surgery.

9. Use of a pharmaceutical composition comprising the solution as defined in any one of claims 1 to 6 and 7 , in the manufacture of a medicament for the treatment of shocks.

10. The use according to claim 9, wherein the solution is suitable for intramuscular injection and/or subcutaneous injection.

11. The use according to claim 9 or claim 10, wherein the pharmaceutical composition is associated with an auto-injection device.

12. The use according to claim 11 which comprises a container prefilled with the pharmaceutical composition as defined in claim 9 or claim 10.

13. The use according to claim 11 comprising two containers wherein one container is prefilled with an aqueous solution of adrenalin, the other one container is prefilled with an aqueous solution of an antidepressant and wherein the pharmaceutical composition as defined in claim 9 or claim 10 is formed by mixing the two solutions within the device.